Drug Makers Must Continue AMP Medicaid Calculations, Despite Court Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
Dec. 19 federal court injunction bars CMS from publishing AMP data for now.
You may also be interested in...
Medicaid AMP: Manufacturers Have Reason To Hope For Significant Changes In Final Rule
A major regulation that could reshape how the pharmaceutical industry reports drug pricing to the government and pays rebates on Medicaid drugs is slated to be released in final form in 2014. Some Medicaid regulatory experts suggest that CMS could make changes in the final rule that will make it less disruptive to manufacturers’ businesses than they have feared.
CMS Makes Headway Toward Part B Drug Price Substitutions
CMS might finally be able to use the Medicare Part B drug price substitution authority provided in the Medicare Modernization Act of 2003, due to the combined effect of the recent redefinition of average manufacturer price for drugs and the proposed Medicare physician fee schedule rule for 2011
CMS Makes Headway Toward Part B Drug Price Substitutions
CMS might finally be able to use the Medicare Part B drug price substitution authority provided in the Medicare Modernization Act of 2003, due to the combined effect of the recent redefinition of average manufacturer price for drugs and the proposed Medicare physician fee schedule rule for 2011